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Abstract
Background: Considering the similarity between the testis-specific isoform of angiotensin-converting enzyme and
the C-terminal catalytic domain of somatic ACE as well as the structural and functional variability of its natural
inhibitors, known as bradykinin-potentiating peptides (BPPs), the effects of different synthetic peptides, BPP-10c
(<ENWPHQIPP), BPP-11e (<EARPPHPPIPP), BPP-AP (<EARPPHPPIPPAP) and captopril were evaluated in the
seminiferous epithelium of male mice.
Methods: The adult animals received either one of the synthetic peptides or captopril (120 nmol/dose per testis)
via injection into the testicular parenchyma. After seven days, the mice were sacrificed, and the testes were
collected for histopathological evaluation.
Results: BPP-10c and BPP-AP showed an intense disruption of the epithelium, presence of atypical multinucleated
cells in the lumen and high degree of seminiferous tubule degeneration, especially in BPP-AP-treated animals. In
addition, both synthetic peptides led to a significant reduction in the number of spermatocytes and round
spermatids in stages I, V and VII/VIII of the seminiferous cycle, thickness of the seminiferous epithelium and
diameter of the seminiferous tubule lumen. Interestingly, no morphological or morphometric alterations were
observed in animals treated with captopril or BPP-11e.
Conclusions: The major finding of the present study was that the demonstrated effects of BPP-10c and BPP-AP on
the seminiferous epithelium are dependent on their primary structure and cannot be extrapolated to other BPPs.
Keywords: B. jararaca, Bradykinin-potentiating peptides, Angiotensin-converting enzyme, Seminiferous epithelium,
Spermatogenesis
Background
Two isoforms of the angiotensin-converting enzyme
(ACE) have been reported in different animals, and
denominated testicular isoform (tACE) and the som-
atic (sACE) isoform [1]. The structural analysis of
both isoforms indicates that tACE harbors only the
C-site of sACE, which is directly associated with male
fertility [1–7]. Furthermore, tACE is expressed in
germ cells in spermatids and spermatozoa, but not in
Sertoli, Leydig or other somatic cells, thereby suggest-
ing that tACE is involved in spermiogenesis [5, 6]. In
contrast, sACE (EC 3.4.15.1) is a peptidase of the cell
membrane of endothelial cells that has two catalytic
sites, the amino-terminal (N-site) and carboxyl-
terminal (C-site) [8, 9]. The N-site metabolizes a pep-
tide hormone (Ac-Ser-Asp-Lys-Pro) associated with
the negative regulation of hematopoiesis [10]. The C-
site converts angiotensin I (Ang I) into angiotensin II
(Ang II), which is a hypertensive peptide and pro-
motes the degradation of bradykinin, a hypotensive
peptide [11, 12].
The first described natural inhibitors of sACE were
bradykinin-potentiating peptides (BPPs) derived from
snake venom. BPPs are oligopeptides rich in proline,
which display bradykinin-potentiating activity, range
from 5 to 14 amino acid residues and display a common
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pyroglutamic acid (<E) residue at the N-terminal pos-
ition and a proline residue at the C-terminal position
[13]. We have demonstrated that synthetic BPPs dis-
play remarkable functional differences despite their
high amino acid sequence similarities [13]. Some
BPPs specifically inhibit the C-site, such as BPP-10c,
while others seem to be either selective for the N-site
or poor ACE inhibitors [14]. Interestingly, biotrans-
formation studies of BPPs with different structural ac-
tivities and the characterization of metabolites in
mouse urine have indicated that the diverse biological
functions of each BPP could be mediated via the pro-
duction of different metabolites due to different inter-
actions with alternative targets [15].
The effect of BPPs derived from Bothrops jararaca
snake venom on spermatogenesis in mice has been char-
acterized by our group. Interestingly, we have demon-
strated that BPP-10c, a potent selective C-domain
inhibitor of sACE and not captopril, modified spermato-
genesis in male Swiss mice treated for 15 consecutive
days with a single dose of BPP-10c (4.7 μmol/kg/d) by
intraperitoneal administration [16].
Intratesticular (i.t.) injection has been employed to
characterize the initial effect ofanti-spermatogenic
molecules, as it optimizes the injected dose and facil-
itates the entry of the molecule of interest in the
testis [17]. Thus, considering the structural and func-
tional particularities of BPPs we selected the different
peptides [BPP-10c (<ENWPHQIPP), BPP-11e (<EAR-
PPHPPIPP), BPP-AP (<EARPPHPPIPPAP), (inv)BPP-
10c (PPIQPHPWNE, containing the inverted BPP-10c
sequence)] and captopril for the assessment of their
effects on the dynamics and structure of the semin-
iferous epithelium in mice following i.t. injection.
Materials and methods
Reagents and synthesis of BPPs
All chemicals were of analytical reagent grade (purity
higher than 95 %) and purchased from Calbiochem-
Novabiochem Corporation (USA), Merck (Germany)
and Sigma-Aldrich Corporation (USA) for peptide
synthesis. Captopril was purchased from Sigma
Chemical Company (USA). BPP-10c, BPP-11e, BPP-
AP and (inv)BPP-10c tested in present study were
synthesized via solid phase peptide synthesis apply-
ing the Fmoc (9-fluorenylmethyloxycarbonyl) strategy
[13–16]. The synthetic peptides were purified by pre-
parative reversed-phase chromatography (reversed-
phase HPLC), whereas the purity and identity of the
peptide were confirmed by MALDI-TOF mass spec-
trometry on an Ettan MALDI-TOF/Pro instrument
(Amersham Biosciences, USA). A purity higher than
95 % was achieved for all peptides.
Animals
Mature male Swiss mice housed with sanitary barriers
from the Central Animal Facility of the Butantan Institute
(São Paulo, Brazil) were authorized for use by the Ethics
Committee of the Butantan Institute (protocol n° 369/07).
The specimens (body weight 30 to 35 g; age 7 to 8 weeks)
received standardized mouse chow (Nuvital Nutrientes
Ltda, Brazil) ad libitum and were housed four animals per
cage, with a 12-h light/dark photoperiod and constant ex-
haust ventilation (Alesco®, Brazil) in the conventional
mammal experimentation animal facility of the Center for
Applied Toxinology (CAT/Cepid), Butantan Institute.
Intratesticular injection of BPPs and captopril
Twenty-five mice were divided into six groups (G1-G6)
and anesthetized with Ketamine® and Xylazine® (3:1) at a
dose of 174 μg and 11.5 μg per gram of body mass, re-
spectively. The animals were submitted to an abdominal
incision (median retro-umbilical longitudinal laparot-
omy), and the right and left testes were exposed in the
abdominal cavity. The agents were injected directly into
the testicular parenchyma of the left testis of each ani-
mal (two sites per testis); approximately 10 μL of syn-
thetic peptide or drug [BPP-10c, BPP-11e, BPP-AP,
(inv)BPP-10c or captopril diluted in 0.91 % w/v aqueous
sodium chloride solution at a concentration of
120 nmol/dose] or vehicle only (control group). Each
sample was administered using a 0.5-mL syringe and a
30-gauge needle (Ultra-Fine Short Needle, BD, Canada)
as detailed by Chung et al. [17].
Following the surgery, the animals were maintained in
the animal facility for seven days and then euthanized by
CO2 asphyxiation. The left testes were collected for mor-
phological and morphometric analysis, although the
specimens were examined with the researchers blinded
to knowledge of the treatment group. Additionally, mor-
phological analysis of the right testes without treatment
was also carried out to assess possible changes caused by
the treatment procedures performed on the left testis in
each animal. All treatments and experiments were per-
formed in duplicate.
Processing of the tissue
The testes were immersed in Bouin fixing solution
(4 % formaldehyde with picric acid) (v/v) for eight
hours, dehydrated in increasing concentrations of alcohol
(70 % to 95 %) (v/v) and embedded in Paraplast® (Sigma
Chemical Company, USA). The histological slices (4 μm
in thickness) were performed on an automatic microtome
(Leica RM 2155; Germany) with a steel blade and
placed in a water bath (42 °C) for placement on glass
slides. Following deparaffinization with xylol and absolute
alcohol-xylol (1:1, v/v), the slices were hydrated in decreas-
ing alcohol solution and stained with either hematoxylin
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and eosin or Mallory’s trichrome stain for morphological
analysis of the seminiferous epithelium.
The periodic acid-Shiff (PAS) with Harris hematoxylin
histochemical method was used to determine the stages
of the seminiferous epithelium cycle. After staining, the
slices were dehydrated and mounted, and the slip-
cover was attached to the slide with Dammar gum.
The preparations were examined using a photomicro-
scope (Axioskop 2, Zeiss, Germany), and the images
were captured with a Pixera digital camera system
(Pixera Corporation, USA) attached to the photomi-
croscope and a microcomputer (Intel® Pentium®) using
the software Adobe Photoshop version 7.0.1 (Adobe
Systems, USA).
Determination of morphological parameters of the
seminiferous epithelium
The degree of tubular degeneration for each treatment
group was analyzed double-blindly, to evaluate the influ-
ence of intratesticular administration of each agent in
the morphology of the seminiferous tubules. The tubules
were classified into four categories: normal tubules (T1);
hypospermatogenic tubules characterized by a decrease
in the thickness of the seminiferous epithelium, which
contained all germ cell types and occasionally sloughed
germ cells (T2); arrested maturation, in which the sem-
iniferous epithelium showed hypospermatogenic areas
joined to others with arrested maturation of germ cells,
predominantly at the level of spermatocytes (T3); and
tubules containing spermatogonia and Sertoli cells or
Sertoli-cell-only tubules (T4). For this purpose, three 4-
μm-thick sections of each testis, which were randomly
selected, were used and 100 tubular cross-sections were
examined from each section. Additionally, the morpho-
logical aspects of the intertubular compartment, in par-
ticular Leydig cells, blood vessels, lymph vessels,
fibroblasts, macrophages, and mast cells, were also
analyzed.
Determination of morphometric parameters of the
seminiferous epithelium
Stages I, V, VII/VIII and XII of the seminiferous epithe-
lium cycle, representing the beginning, middle and end
of this cycle, respectively, were selected for the blind
analysis of cell numbers and morphometric parameters
of the seminiferous epithelium [18]. Each stage was
identified based on acrosome development and morph-
ology of the nucleus of the spermatids during differenti-
ation [19]. For morphometric analysis, eight circular or
nearly circular seminiferous tubules were randomly se-
lected in each stage studied per testis. The images cap-
tured were analyzed using the software ImageJ (National
Institutes of Health, USA) to assess the diameter of the
seminiferous tubules (mm), thickness of the seminiferous
epithelium (mm) and diameter of the seminiferous tubule
lumen (mm).
Quantitative analysis of the cells in the seminiferous
epithelium
The images used for morphometric analysis were also
utilized for quantitative analysis. The images were ana-
lyzed with the aid of Adobe Photoshop version 7.0.1
(Adobe Systems, USA), with a reticulated grid of 1575
points at 66.7 % magnification. Only the nuclei of the
cells in the intersection points were counted. The fol-
lowing cell types were counted for each stage (I, V, VII/
VIII, and XII) of the seminiferous epithelium cycle: type
A spermatogonium, type B spermatogonium, prelepto-
tene spermatocyte, zygotene spermatocyte, meiotic fig-
ures, secondary spermatocytes, pachytene spermatocyte,
round spermatid and Sertoli cells.
Total support capacity of each Sertoli cell
Assessment of the total support capacity was performed
with the data derived from the quantitative analysis, div-
iding the total number of germ cells by the total number
of Sertoli cells per stage, based on the protocol described
by Russell and Peterson [20].
Statistical analysis
The software GraphPad Prism (version 4.0; GraphPad
Software, Incorporation) was used for statistical analyses.
Statistical significance for all experiments was analyzed
using one-way analysis of variance (ANOVA) followed
by the Tukey test as a post hoc test. Values represent the
mean ± SEM, and p < 0.05 was considered statistically
significant.
Results
Morphological analysis of the seminiferous epithelium
The analysis of the testes of mice treated with saline so-
lution, captopril, and (inv)BPP-10c indicated that these
molecules do not alter the morphological characteristics
of the seminiferous epithelium with regard to the ar-
rangement of germ cells and integrity of the tubule and
interstitial compartment, considering the seminiferous
epithelium cycle (I-XII) [Fig. 1, panels C, CAP, (inv)10c].
In contrast, the seminiferous epithelium of animals
treated with BPP-10c displayed an absence of elongated
spermatids in the seminiferous tubules at stages I, V and
VII/VIII of the seminiferous epithelium cycle as well as
the presence of developing germ cells, immature germ
cells in the seminiferous tubule lumen, discontinuity of
the seminiferous epithelium caused by the displacement
of germ cells of the adjacent epithelium and ruptures in
the seminiferous epithelium (Fig. 1, panel 11e).
Interestingly, BPP-11e did not cause alterations in the
seminiferous epithelium compared with the control
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group (Fig. 1, panel 11e). Moreover, BPP-AP demon-
strated more intensive impairment of spermatogen-
esis in the seminiferous tubules (Fig. 1, panel ap)
compared with that observed following BPP-10c
treatment. Hypospermatogenic seminiferous tubules
with Sertoli cells only were identified, along with an
intensive loss of germ cells in the lumen, an absence
of elongated spermatids at stages I, V, VII/VIII and
immature germ cells in the lumen of the seminifer-
ous tubules (Fig. 1, panel ap). Additionally, no
changes were observed in the intertubular compart-
ment of the animals treated with BPPs tested or
captopril.
Degree of tubule degeneration
The degree of tubule degeneration (Table 1), according to
the four-category scale and based on the mean of tubule
types present in each group, was significantly different in
the BPP-10c and BPP-AP groups compared to the control
group. Meanwhile, no significant difference was found
Fig. 1 Effects of angiotensin-converting enzyme (ACE) inhibitors on morphology of the seminiferous epithelium of the mouse testis. Seminiferous
tubules of the right testis of control animals treated with saline solution (C) and the left testis of mice treated with captopril (CAP), (inv)BPP-10c
[(inv)10c], BPP-10c (10c), BPP-11e (11e) or BPP-AP (AP). Normal structure of tubules [C, CAP, (inv)10c, and 11e], germ cells in the lumen oftubules
(10c, black arrow), degenerative tubule (10c and AP, red arrow), ruptures in the epithelium (10c, arrowheads), absence of round spermatids in stage V
of the seminiferous epithelium cycle (10c, asterisk), round spermatids in the adluminal compartment (AP, double asterisk) and tubules with few germ
cells, green arrow). Staining: Mallory’s Trichrome [C, CAP, (inv)10c and 10c] and PAS-Hematoxylin (11e and AP)
Table 1 Semi-quantitative histological assessment of
seminiferous tubules of mouse testes
Treatment T1 (%) T2 (%) T3 (%) T4 (%)
C 92.33 ± 1.20 10.33 ± 0.89 0 0
CAP 94.32 ± 1.02 5.66 ± 1.12 0 0
10c 49.67 ± 0.88* 38.32 ± 1.43* 12.01 ± 0.57* 0
(inv)10c 92.65 ± 0.86 7.36 ± 0.78 0 0
11e 91.67 ± 1.48 8.39 ± 0.90 0 0
AP 37.69 ± 2.35* 55.63 ± 3.06* 5.00 ± 0.53* 1.62 ± 0.23*
The data are presented as the mean ± SEM. Types of degeneration tubular
in each treatment [CAP, 10c, inv(10c), 11e and AP] were compared to the
control (C), and significant differences as assessed through one-way
ANOVA followed by the Tukey test as a post hoc test (* p < 0.05). Normal
tubules (T1); hypospermatogenic tubules (T2); arrested maturation tubules
(T3); tubules containing spermatogonia and Sertoli cells or Sertoli-cell-only
tubules (T4). C, control; CAP, captopril; (inv)10c, containing the inverted
BPP-10c sequence; 10c, BPP-10c; 11e, BPP-11e; AP, BPP-AP
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between the control groups (right testis and left testis) (data
not shown) or between the BPP-11e, (inv)BPP-10c or cap-
topril groups and the control group. Additionally,
arrested maturation of the tubules was observed only
in the BPP-10c and BPP-AP treatment groups, while
tubules containing only spermatogonia and Sertoli
cells were detected in the BPP-AP treatment group.
Morphometric analysis of the seminiferous epithelium
BPP-10c treatment displayed a reduction in the
thickness of the seminiferous epithelium and an in-
crease in the diameter of the seminiferous tubule
lumen compared with the (inv)BPP-10c, BPP-11e,
captopril and control groups (Fig. 2 –a). Treatment with
BPP-AP led to a significant reduction in the thickness of
the seminiferous epithelium and an increase in the diam-
eter of the seminiferous tubule lumen compared with the
BPP-11e, captopril and control groups (Fig. 2 – a). No alter-
ation was detected in the diameter of tubules in all treat-
ment groups.
Total support capacity of each Sertoli cell
Treatment with BPP-10c led to a reduction in total
support capacity of each Sertoli cell in stages I, V
and VII/VIII compared with the (inv)BPP-10c, BPP-
11e, captopril and control groups (Fig. 2b). Likewise,
Fig. 2 Morphometric aspects of the seminiferous tubules in mice treated with angiotensin-converting enzyme (ACE) inhibitors. a Thickness of the
epithelium and diameter of tubules and lumen of the seminiferous tubules of control and treated animals. b Total support capacity of Sertoli cells
during stages I, V, VII/VIII and XII of the seminiferous epithelium cycle of control and treated animals. The data are presented as the mean ± SEM.
The various letters indicate significant differences between the analyzed groups as determined via one-way ANOVA followed by the Tukey test
as a post hoc test (a, p < 0.001; b, p < 0.0001). C, control; CAP, captopril; (inv)10c, containing the inverted BPP-10c sequence; 10c, BPP-10c; 11e,
BPP-11e; AP, BPP-AP
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treatment with BPP-AP also led to a significant re-
duction in total support capacity of each Sertoli cell
in stages I, V, VII/VIII and compared with the con-
trol, captopril and BPP-11e groups (Fig. 2b), and spe-
cifically in stage XII.
Quantitative analysis of the cells in the seminiferous
epithelium
Spermatocytes in pachytene and round spermatid num-
bers were significantly reduced in stages I, V and VII/
VIII of the seminiferous epithelium cycle in the BPP-10c
and BPP-AP groups (Fig. 3 – a, b, c) compared with the
control, captopril, (inv)BPP-10c and BPP-11e groups.
BPP-AP also led to a reduction in the number of prelep-
totene spermatocytes and round spermatids in stages
VII/VIII compared with the BPP-11e and control groups
(Fig. 3 – c). Moreover, only BPP-AP led to a reduction
in the number of meiotic figures and secondary sper-
matocytes at stage XII, which is the end of the seminifer-
ous epithelium cycle (Fig. 3 – d). No differences were
detected in the number of Sertoli cells in all treatment
groups and all stages tested.
Discussion
The major finding of the present study was the observa-
tion that the effects of BPP-10c and BPP-AP on the sem-
iniferous epithelium are dependent on their primary
structure and cannot be extrapolated to other BPPs.
Interestingly, captopril and BPP-11e, which are also
sACE inhibitors, did not show any changes in the struc-
ture of the seminiferous epithelium. Considering the
structural similarity between the C-terminal sites of
sACE and tACE [] and the observation that male tACE
“knockout” mice are hypofertile, ACE inhibitors may re-
duce male fertility [21–23]. Captopril, lisinopril and
enalapril have been reported to act as tACE inhibitors in
vitro [21, 24, 25]. Likewise, BPP-5a (<EKWAP) and BPP-
9a (<EWPRPQIPP), which are natural sACE inhibitors,
are also tACE inhibitors in vitro, acting at the nanomolar
level [26, 27]. Nevertheless, it has been demonstrated
that captopril and its derivatives did not affect tACE ac-
tivity in vivo, thereby suggesting that these drugs do not
cross the BTB, which would explain the absence of re-
ports concerning the adverse effects of ACE inhibitors
on testicular function [28, 29]. However, we have dem-
onstrated in previous studies that BPP-10c, the most po-
tent and selective sACE C-domain inhibitor, modified
spermatogenesis in mice treated by intraperitoneal injec-
tion without affecting BTB permeability or the distribution
of claudin-1, a protein found at the site of the BTB [16].
It was very interesting to find that the effects are
dependent on the primary molecular structure of BPP-10c,
since no morphological or morphometric alterations in
the seminiferous epithelium were found in the mice
treated with (inv)BPP-10c, that contains the inverted
BPP-10c sequence.
Experimental evidence from our group has demon-
strated that BPPs interact in vivo with other molecular
targets in addition to sACE [13]. We have demonstrated
that BPP-10c is capable of positively modulating the
catalytic activity of argininosuccinate synthase (AsS) in
vitro and in vivo and consequently induces NO produc-
tion in endothelial cells [30]. AsS is a ubiquitous enzyme
that can be detected in the lungs, brain and testes [31].
AsS catalyzes the conjugation reaction of citrulline with
aspartate, thereby generating argininosuccinate with the
uptake of adenosine triphosphate (ATP). Argininosucci-
nate is a substrate of argininosuccinate lyase (AsL),
which converts it into L-arginine, a substrate of nitric
oxide synthase (NOS) in the production of nitric oxide
(NO) [31]. NO is one of the mediators that control the
opening and closing of the junctional complexes in the
seminiferous epithelium via the NO/soluble guanylate
cyclase/cGMP protein kinase G/b-catenin signaling
pathway [32]. This mechanism contributes to the control
of migration of developing germ cells from the basal
compartment to the adluminal compartment seminifer-
ous epithelium [33].
BPP-10c caused ruptures in the seminiferous epithe-
lium and loss of germ cells in the lumen of the semin-
iferous tubules, typical alterations in the dynamics of
junctional complexes (occludin and adherens junctions)
in the seminiferous epithelium [32–34]. Thus, as BPP-
10c caused ruptures in the epithelium and acts as a posi-
tive modulator of AsS, these peptides can increase the
levels of NO in the testis, thereby causing the opening of
the junctional complexes and the appearance of imma-
ture germ cells in the seminiferous tubule lumen. How-
ever, new experiments should be designed to confirm
this hypothesis.
We also show that the presence of immature germ
cells in the lumen of the seminiferous tubules and dis-
continuity and ruptures of the seminiferous epithelium
were more evident in the BPP-AP treatment group than
in the BPP-10c group. Yet another interesting result was
the effects of BPP-11e (<EARPPHPPIPP) and BPP-AP
(<EARPPHPPIPPAP) on spermatogenesis in mice. We
demonstrated that the presence of the alanine and pro-
line amino acids in the C-terminal portion of BPP-AP
was essential for the effects observed, which once again
demonstrates that the varying effects of different BPPs
on spermatogenesis in mice is attributed to their primary
structure.
BPP-AP and BPP-11e were identified in venom derived
from the snake Bothrops jararacussu using the inactive
zinc metalloprotease thimet oligopeptidase (EP24.15) as
a peptide bait to isolate specific bioactive peptides from
complex mixtures [35]. BPP-AP displayed an inhibitory
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effect on sACE (0.035 μM) and EP24.15 (1.6 μM), which
are lower than the BPP-11e values observed (0.084 μM
and 9.5 μM, respectively) [35]. EP24.15 is found predom-
inantly in the neuroendocrine–gonadal axis, where it is
implicated in the progression of spermatogenesis [36].
However, the discrete differences in Ki between the two
BPPs in vitro are insufficient to explain the intensive ef-
fects of BPP-AP on spermatogenesis in mice and the ab-
sence of alterations following BPP-11e treatment in vivo.
In contrast, in vivo assays have suggested that BPP-AP,
but not BPP-11e, can induce the release of vasodilatation
mediators and increase the expression of integrins in
both leukocytes and on the surface of endothelial cells,
thereby leading to adhesion and extravasation of rolling
leukocytes [35]. Similarly, we also demonstrate that only
BPP-AP promotes changes in morphology of the semin-
iferous epithelium, which may be associated with the
minor structural differences between these peptides.
We have previously shown that BPP-10c is internalized
by HUVEC, HEK293 and C6 cells in different experi-
mental conditions [16, 30, 37]. These results are not sur-
prising considering that BPPs are proline-rich peptides,
a feature that endows these molecules with the proper-
ties of cell-penetrating peptides and resistance to prote-
olysis [27]. These data indicate that these peptides may
be internalized by Sertoli cells; however, the different ef-
fects observed in the seminiferous epithelium of mice
treated with different proline-rich peptides and the
hypothesis that these peptides are internalized by Sertoli
cells are not sufficient to explain the pathogenic variations,
as BPP-11e did not demonstrate effects in the seminiferous
epithelium. BPPs have shown remarkable functional differ-
ences, despite their high amino acid sequence similarities;
furthermore, new targets that shed light on their biological
activities have been identified [13].
We have tested a number of BPPs with different structure
activities [i.e., BPP-5a (<EKWAP), BPP-7a (<EDGPIPP),
BPP-9a (<EWPRPQIPP), BPP-10c (<ENWPHQIPP) and
BPP-12b (<EWGRPPGPPIPP)] and studied their sta-
bility when exposed to endogenous animal proteolytic
enzymes in mice [16, 38]. Sequence analysis of urin-
ary metabolites of BPPs, performed via MALDI-TOF
mass spectrometry, generated the following findings: BPP-
7a showed increased resistance to proteolytic cleavage;
BPP-5a was totality metabolized into < EKW; BPP-9a
was identified in the intact form as well as the < EWPRP
and < EWPRPQIP forms; BPP-10c was found in its intact
form and as a unique metabolite (<ENWPHQIP); and
BPP-12a proved to be highly susceptible to hydrolysis
by proteolytic enzymes [16, 38]. Thus, the results ob-
tained support the hypothesis that the diverse biological
functions of each BPP may be mediated by different inter-
actions with alternative targets and not only by sACE
inhibition.
In fact, we showed that BPP-10c was capable of posi-
tively modulating the catalytic activity of AsS in vitro
and in vivo and consequently induced NO production in
endothelial cells, which explains the hypotensive effect
independent of sACE inhibition [30]. In the present
study, we hypothesized that the presence of the C-
terminal portion of BPP-AP was important for produ-
cing the effects observed in the seminiferous epithelium
compared with BPP-11e, which may be explained by the
specificity of interaction with unknown targets.
Conclusion
Overall, the results obtained from the proline-rich
snake-venom oligopeptide suggest that the alterations in
the structure of the seminiferous epithelium in mice fol-
lowing BPP-10c and BPP-AP treatment, but not treat-
ment with BPP-11e, are dependent on their primary
molecular structure. This study offers new perspectives
for the elucidation of possible mechanisms involved in
the impairment of spermatogenesis by BPP-10c and
BPP-AP, thereby providing new insight into the bio-
logical features of the snake venom.
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Fig. 3 The effects of angiotensin-coverting enzyme (ACE) inhibitors on the number of germ cell types in the seminiferous epithelium cycle. The
germ cells present at stages (a) I, (b) V, (c) VII/VIII, and (d) XII of the seminiferous epithelium cycle were counted in all conditional treatments. The
data are presented as the mean ± SEM; various superscripts designate significant differences between the analyzed groups as assessed using one-
way ANOVA followed by the Tukey test as a post hoc test (a, p < 0.01; b, p < 0.001; c, p < 0.0001). SC, Sertoli cell; SPG(A), type A spermatogonium;
SPG(B), type B spermatogonium; SP(Pl), preleptotene spermatocyte; SP(Z), zygotene spermatocyte; SP(P), pachytene spermatocyte; MF, meiotic
figures; SS, secondary spermatocyte; RP, round spermatid; C, control; CAP, captopril; (inv)10c, containing the inverted BPP-10c sequence; 10c,
BPP-10c; 11e, BPP-11e; AP, BPP-AP
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